Skip to main content
Terug
Watch Compare

Serina Therapeutics, Inc.

Datakwaliteit: 100%
SER
NYSE Manufacturing Chemicals
€ 1,98
▼ € 0,02 (-1,00%)
Marktkapitalisatie: 23,95 M
Prijs
€ 1,95
Marktkapitalisatie
23,95 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -2,52% annually over 5 years
Negative free cash flow of -18,01 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 134,66%
Capital intensive — 45,38% of revenue goes to capex

Groei

Revenue Growth (5Y)
-2,52%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)132,14%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-1077,04%
Onder sectorgemiddelde (-53,58%)
ROIC-421,53%
Net Margin-14755,38%
Op. Margin-18478,46%

Veiligheid

Debt / Equity
N/A
Current Ratio1,31
Interest Coverage-112,78

Waardering

PE (TTM)
-1,25
Boven sectorgemiddelde (-1,48)
P/B Ratio13,61
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -1,3 -1,5
P/B 13,6 1,6
ROE % -1077,0 -53,6
Net Margin % -14755,4 -41,5
Rev Growth 5Y % -2,5 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 1,98
+455.6%
Koersdoel
€ 11,00
€ 11,00
€ 11,00
€ 11,00
Vooruitzicht
Forward K/W -1,89
Forward WPA -€ 1,05
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,05
-€ 1,05 – -€ 1,05
 0,0 1
FY2026 -€ 1,41
-€ 1,41 – -€ 1,41
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,50 -€ 0,31 +38,0%
Q32025 -€ 0,53 -€ 0,51 +3,1%
Q22025 -€ 0,43 -€ 0,66 -55,3%
Q12025 -€ 0,62 -€ 0,49 +21,0%

ETFs Holding This Stock

BRSIX BRSIX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 132,14% Revenue Growth (3Y) -4,32%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -2,52% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 130.000,0 Net Income (TTM) -19,18 M
ROE -1077,04% ROA -179,66%
Gross Margin N/A Operating Margin -18478,46%
Net Margin -14755,38% Free Cash Flow (TTM) -18,01 M
ROIC -421,53% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,31
Interest Coverage -112,78 Asset Turnover 0,01
Working Capital 2,71 M Tangible Book Value 1,76 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,25 Forward P/E N/A
P/B Ratio 13,61 P/S Ratio 184,24
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -75,21%
Market Cap 23,95 M Enterprise Value 15,33 M
Per Share
EPS (Diluted TTM) -1,91 Revenue / Share 0,01
FCF / Share -1,46 OCF / Share -1,46
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 45,38% FCF Conversion 93,91%
SBC-Adj. FCF -20,07 M Growth Momentum 134,66

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 130.000,0 56.000,0 142.000,0 34.000,0 144.000,0
Net Income -19,18 M -11,14 M -14,80 M -10,46 M -8,68 M
EPS (Diluted) -1,91 -1,51 -13,72 — —
Gross Profit — — 102.000,0 21.000,0 125.000,0
Operating Income -24,02 M -17,05 M -9,89 M -6,98 M -7,93 M
EBITDA — — — — —
R&D Expenses 13,16 M 7,48 M 734.000,0 1,03 M 1,46 M
SG&A Expenses — — — — —
D&A 100.000,0 194.000,0 — — 699.000,0
Interest Expense 213.000,0 526.000,0 4,90 M 3,34 M —
Income Tax 18.000,0 0,0 — — -150.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,95 M 6,72 M 11,97 M 3,24 M 3,15 M
Total Liabilities 6,99 M 6,22 M 6,61 M 20,56 M 15,03 M
Shareholders' Equity -37.000,0 641.000,0 5,47 M -17,21 M -11,83 M
Total Debt — — — 18,12 M —
Cash & Equivalents 3,06 M 3,67 M 345.000,0 645.000,0 584.000,0
Current Assets 6,08 M 5,68 M 754.000,0 2,45 M 2,23 M
Current Liabilities 3,56 M 2,37 M 5,91 M 10,08 M 8,97 M